Dror Bashan - Apr 1, 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Dror Bashan
Stock symbol
PLX
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/3/2024, 05:30 PM
Previous filing
Sep 9, 2022
Next filing
Aug 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +264K +14% 2.15M Apr 1, 2024 By Trust F1, F2
holding PLX Common Stock 133K Apr 1, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan").
F2 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.